NCI-H358Homo sapiens (Human)Cancer cell line
Also known as: H358, H-358, NCIH358, H1358 (In table 1.)
Quick Overview
Human lung cancer cell line with club cell origin, used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1559 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Male |
Disease Information
| Disease | Minimally invasive lung adenocarcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenocarcinoma |
| OncoTree Code | LUAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000860_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | TP53 | - | Homozygous | 2 out of 3 copies | from parent cell line HL-60 |
| MutationSimple | CTNNB1 | p.Thr75Ala (c.223A>G) | Heterozygous | - | from parent cell line NCI-H358 |
| MutationSimple | KRAS | p.Gly12Cys (c.34G>T) | Unspecified | - | PubMed=21173094 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Gazdar A.F.
Oncogene 7:171-180(1992).
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Linnoila R.I.
Oncogene 7:743-749(1992).
Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.
Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.
J. Natl. Cancer Inst. 82:1420-1426(1990).
Peripheral airway cell differentiation in human lung cancer cell lines.
Clark J.C., Whitsett J.A.
Cancer Res. 50:5481-5487(1990).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.
Cancer Res. 46:798-806(1986).
Mutations and altered expression of p16INK4 in human cancer.";
Harris C.C.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).
Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.
Lokshin A.E., Levitt M.L.
J. Cell. Biochem. Suppl. 24:186-197(1996).
Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.
Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.
Br. J. Cancer 77:2162-2170(1998).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.
Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.
Cancer Genet. Cytogenet. 125:87-99(2001).
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.
Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K.
Oncogene 20:4249-4257(2001).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Cell 131:1190-1203(2007).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
Reconstructing targetable pathways in lung cancer by integrating diverse omics data.
Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.
Nat. Commun. 4:2617.1-2617.13(2013).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.
Minna J.D., Wistuba I.I., Pertsemlidis A.
Oncotarget 9:29601-29618(2018).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
The cancer SENESCopedia: a delineation of cancer cell senescence.";
Leite de Oliveira R., Wessels L.F.A., Bernards R.
Cell Rep. 36:109441.1-109441.22(2021).
Proteomic and ultrastructural analysis of Clara cell and type II alveolar epithelial cell-type lung cancer cells.
Hou W.-L., Chang M., Liu X.-F., Hu L.-S., Hua S.-C.
Transl. Cancer Res. 9:565-576(2020).